

Index

A

Abnormal lung function, 70–73
Acquired subglottic stenosis, 7
Active sleep (AS), 162
Airflow obstruction, 101
Air pollution, 147–148
Airway disease
 behavioral and lifestyle issues, 106
 extrapulmonary, 106
 normal development, 103–104
 pulmonary, 104–106
Airway hyperresponsiveness, 36
Airway inflammation, 104
Airway obstruction, 71, 72
Airway outcomes
 base of tongue, 182
 glottis, 184–185
 SGS
 congenital, 186, 187
 definition, 186
 elliptical cricoid, 186, 187
 epidemiology, 187
 pathophysiology, 188
 treatment, 188–190
 supraglottis, 183–184
 trachea, 190–192
Airway reactivity
 abnormal airway function
 hyperoxic exposure, 36–38
 infectious/inflammatory contribution,
 39–40
 pressure effects, 38–39
 cholinergic efferent output, 32–33
 lower airways
 NANC control, 34–35

 sympathetic control, 34
 maturational changes, 31–32
Airway-related vagal preganglionic neurons
 (AVPNs), 32
Airway smooth muscle
 contraction, 38
 development, 31
 extrinsic sympathetic innervation of, 34
Airway smooth muscle contraction, 38
Alveolar stages, 64
Antenatal infection and inflammation
 bacterial sepsis, 219–220
 chorioamnionitis, 216
 causes, 217–218
 lung susceptible, 218–219
 Ureaplasma spp., 216–217
Asthma, 16–17

B

Brain-derived neurotrophic factor (BDNF), 37,
 38
Breast-feeding, 150
Breathing
 control
 abnormal, 110
 immature, 6
 sleep outcomes
 adolescents and young adults, 171–172
 middle childhood and obstructive sleep
 apnea syndrome, 169–171
 postconceptual age, 163–165
 preschool children, 167–169
 SDB, 166
 SIDS, 165–166

- Bronchial hyperresponsiveness, 105
- Bronchopulmonary dysplasia (BPD)
- bacterial sepsis, 219–220
 - clinical definitions, 45–47
 - clinical manifestations, 1
 - clinical practice and trials, 55–56
 - CMV infection, 220–221
 - description, 45–46
 - development, 18
 - diagnosis, 15
 - nonpulmonary outcomes, 54–55
 - pulmonary function, 51, 54
 - respiratory morbidity outcomes, 50–53
 - genetic factors, 3
 - infants with, 2
 - long-term respiratory outcomes, 66
 - abnormal pulmonary function, 70–73
 - late-preterm-born infants, 73–74
 - radiographic abnormalities, 70
 - respiratory symptoms, 67–68
 - structural abnormalities, 68–70
 - management, 2
 - newer criteria
 - asthma, 16–17
 - mild, 16
 - moderate, 16
 - severe, 16
 - wheezing, 16
 - pathogenesis, 64–67
 - PH in, 197
 - abnormal pulmonary circulation, 199–201
 - diagnostic approach, 201–205
 - high mortality associated with, 198
 - treatment, 206–210
 - physiologic definitions, 48–50
 - prenatal risk factors, 2
 - respiratory viral infection, 221–223
 - severity, 47
- C**
- Calcium channel blockers (CCB), 209
- Cannalicular stages, 63
- Cardiac catheterization, 204–205
- Chest computed tomography (CT), 90–91
- Chest radiograph (CXR), 89–90
- Chorioamnionitis, 216
- causes, 217–218
 - lung susceptible, 218–219
- Chronic lung disease. *See* Bronchopulmonary dysplasia (BPD)
- Chronic obstructive pulmonary disease (COPD), 139
- Circadian rhythms
- in adolescents and adults, 175–176
 - neonatal period, 172
- Congenital SGS, 186, 187
- Connective tissue growth factor (CTGF), 66
- Continuous positive airway pressure (CPAP), 39, 101
- CXR. *See* Chest radiograph (CXR)
- Cytomegalovirus (CMV) infection, 220–221
- D**
- Developmental Origins of Health and Disease Hypothesis (DOHAD), 111
- Diffusion capacity of the lung for carbon monoxide (DL_{CO})
- parenchymal disease, 107
 - PFT, 86
 - in school-age children born, 88
- DOHAD. *See* Developmental Origins of Health and Disease Hypothesis (DOHAD)
- E**
- Echocardiograms, 204
- Electrocardiograms, 204
- Embryonic stages, 63
- EPICure study, 20
- F**
- Forced expiratory flows (FEF), 84–85
- Functional residual capacity (FRC), 50
- G**
- Gastroesophageal reflux (GER), 184
- Gestational age (GA)
- primary complication, 124, 126
 - on readmission rates, impact, 125–126
 - readmissions, 124–126
 - unadjusted total readmission rates, 121–124
- Glossoptosis, 182
- Glottis, 184–185
- H**
- High-resolution computerized tomography (HRCT), 108
- Humidified high flow nasal cannula (HHFNC), 49

I

- Immature airway, 33
- Inflammation, 23
- Inhaled nitric oxide (iNO), 206
- Intergenerational smoking cessation, 141–142
- Intra-amniotic inflammation (IAI), 217
- Intrauterine growth restriction (IUGR), 148

L

- Large airways disease, 4
- Laryngomalacia, 183
- Left ventricular diastolic dysfunction (LVDD), 205
- Lipopolysaccharide (LPS), 39
- Lung clearance index (LCI), 86
- Lung development
 - after maternal smoking in pregnancy, 143–144
 - stages, 62
 - alveolar, 64
 - cannalicular, 63
 - embryonic, 63
 - pseudoglandular, 63
 - saccular, 64
- Lung function
 - in older children and adults born prematurely
 - DLCO, 88
 - evolution, 88–89
 - measurements, 88
 - spirometry, 87–88
 - in preschool aged preterm children, 86–87
- Lung parenchymal disease, 37. *See also*
 - Bronchopulmonary dysplasia (BPD)

M

- Magnetic resonance imaging (MRI), 91–92
- Maldevelopment, 22
- Maximal flow at functional residual capacity (V_{max}FRC), 84–85
- Mechanical ventilation, 66
- Muscarinic receptors, 33
- Myosin phosphatase (MYPT), 38

N

- Neurotrophin family, 37
- Nicotine replacement therapies (NRT), 146
- Nonadrenergic noncholinergic (NANC) control, 34–35
- Nonrapid eye movement (NREM) sleep, 162–163

O

- Obstructive sleep apnea syndrome (OSAS), 166, 169
- Outpatient health care use, 128–130
- Oxygen toxicity, 65

P

- Parenchymal disease
 - alveolar hypoplasia, 107
 - focal parenchymal abnormalities, 108–109
- Persistent radiographic abnormalities, 70
- Persistent structural abnormalities, 71
- PFT. *See* Pulmonary function testing (PFT)
- Pierre Robin sequence (PRS), 182
- Polysomnograms (PSGs), 165, 168
- Postdischarge health care use, 119
 - conceptual framework, 131
 - emergency department visits, 128
 - gestational age and infant complications, 124–126
 - hospital and outpatient care role, 131–132
 - moderate and late preterm infants, 133
 - prematurely born infants, 120–124
 - preterm infants, 133
 - RSV hospitalizations, 126–127
 - social determinants of health, 132
- Post neonatal intensive care unit (NICU)
 - respiratory morbidity
 - lung trajectories, 139–140
 - perinatal interventions, 149
 - postnatal interventions
 - avoiding early postnatal pollution exposure, 151
 - growth and nutrition, 149–150
 - personal smoking, 152
 - research opportunities, 154
 - second hand smoke, 150–151
 - viral infections, 151–152
 - preconception interventions
 - intergenerational smoking cessation, 141–142
 - maternal nutrition and weight preconception, 141
 - prenatal interventions to decrease air pollution, 147–148
 - normalizing or maximizing prenatal growth, 148
 - in utero smoke/tobacco/nicotine exposure, 142–147
 - preterm birth epidemiology and complications, 140
 - treatment, 153
- Preconception smoking cessation, 141–142

- Prematurity. *See* Sequelae of prematurity
- Preterm birth
- BPD. *See* Bronchopulmonary dysplasia (BPD)
 - complications, 21
 - definition, 15
 - epidemiology and complications, 140
 - gestational age, 21
 - nonrandomized trials, 25
 - putative mechanisms
 - inflammation, 23
 - lung growth, 22–23
 - structural changes, 24
 - respiratory problems, 24–25
 - pathophysiology, 21–22
 - prevalence, 20, 21
 - respiratory symptoms, 17–19
 - sleep architecture, 173
 - wheezing, 19–21
- Preterm delivery, 149
- Pseudoglandular stages, 63
- Pulmonary circulatory disease, 111
- Pulmonary function testing (PFT)
- chloral hydrate, 82
 - DL_{CO}, 86
 - dynamic respiratory mechanics, 82
 - FEF, 84–85
 - lung compliance, 81
 - lung volume measurements, 85–86
 - passive expiratory mechanics, 82–84
 - tidal breathing measurements, 84
 - in utero smoke/tobacco/nicotine exposure, 143–144
 - ventilation homogeneity measurements, 86
- Pulmonary hypertension (PH), 197. *See also* Bronchopulmonary dysplasia (BPD)
- abnormal pulmonary circulation, 199–201
 - diagnostic approach, 201–205
 - high mortality associated with, 198
 - in preterm infants, 5
 - treatment, 206–210
- Pulmonary vascular disease (PVD), 200
- Q**
- Quiet sleep (QS), 162
- R**
- Raised volume RTC (RVRTC) technique, 85
- Rapid eye movement (REM) sleep, 162–163
- Rapid thoracoabdominal compression (RTC) technique, 85
- Respiratory inductance plethysmography (RIP), 84
- Respiratory symptoms, 66
- Respiratory syncytial virus (RSV)
- hospitalizations, 126–127
 - infection, 25, 74
- Respiratory tract infections (RTI), 151
- Respiratory viral infection, 221–223
- S**
- Saccular stages, 64
- SDB. *See* Sleep-disordered breathing (SDB)
- Second hand smoke (SHS), 150–151
- Sequelae of prematurity
- adult survivor management, 112
 - airway disease
 - behavioral and lifestyle issues, 106
 - extrapulmonary, 106
 - normal development, 103–104
 - pulmonary, 104–106
 - 2012 and 2015 meta-analysis, 102
 - breathing, abnormal control of, 110
 - consequences, 101
 - CPAP, 101
 - DOHAD, 111
 - impaired exercise performance, 109–110
 - interlocking reasons, 100
 - neonatal ventilation, 101
 - parenchymal disease
 - alveolar hypoplasia, 107
 - focal parenchymal abnormalities, 108–109
 - preterm birth, 99
 - preterm survivors, 100
 - pulmonary circulatory disease, 111
 - respiratory symptoms and morbidity, 102–103
- SGS. *See* Subglottic stenosis (SGS)
- SIDS. *See* Sudden infant death syndrome (SIDS)
- Sleep-disordered breathing (SDB)
- adolescents and young adults, 171–172
 - in preschool children, 167–169
 - middle childhood, 169–171
 - OSAS, 166, 169
- Sleep outcomes
- breathing
 - adolescents and young adults, 171–172
 - middle childhood and obstructive sleep apnea syndrome, 169–171
 - postconceptual age, 163–165
 - preschool children, 167–169
 - SDB, 166
 - SIDS, 165–166

- circadian rhythms
 - in adolescents and adults, 175–176
 - neonatal period, 172
 - patterns and behaviors, 173–175
 - respiratory control, 162–163
 - sleep architecture, 173
 - sleep state maturation, 162–163
 - Small airways disease, 3–4
 - Smoking cessation programs, 144–146
 - Social determinants of health, 132
 - Subglottic cysts, 7
 - Subglottic stenosis (SGS)
 - acquire, 7
 - congenital, 186, 187
 - definition, 186
 - elliptical cricoid, 186, 187
 - epidemiology, 187
 - pathophysiology, 188
 - treatment, 188–190
 - Sudden infant death syndrome (SIDS), 165–166
 - Supraglottis, 183–184
- T**
- Trachea, 190–192
 - Tracheobronchomalacia (TBM), 191–192
 - Tracheoesophageal fistula (TEF), 191
 - Tracheomalacia (TM), 190–192
 - Tracheostomy, 182
 - Tricuspid regurgitant jet (TRJV), 204
- U**
- Upper airway obstruction, 181
 - during infancy, 6
 - prevalence, 7
 - risk factors, 7
 - Ureaplasma parvum*, 216
 - Ureaplasma urealyticum*, 216
- V**
- Vascular disease, 5
 - Vascular endothelial growth factor (VEGF), 200, 218
 - Very low birth weight infant (VLBW), 124
 - Vitamin C supplementation, 146–147
- W**
- Wheezing, 16, 19–21. *See also* Preterm birth
 - inflammation, 23–24
 - lung growth, 23
 - structural changes, 24